Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-Current Deffered Revenue (2020 - 2025)

Cytek Biosciences' Non-Current Deffered Revenue history spans 6 years, with the latest figure at $18.3 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 13.92% year-over-year to $18.3 million; the TTM value through Dec 2025 reached $18.3 million, up 13.92%, while the annual FY2025 figure was $18.3 million, 13.92% up from the prior year.
  • Non-Current Deffered Revenue reached $18.3 million in Q4 2025 per CTKB's latest filing, up from $16.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $18.3 million in Q4 2025 to a low of $6.3 million in Q2 2021.
  • Average Non-Current Deffered Revenue over 5 years is $13.3 million, with a median of $14.8 million recorded in 2024.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 183.28% in 2021, then dropped 12.4% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $9.8 million in 2021, then soared by 34.06% to $13.1 million in 2022, then grew by 15.3% to $15.1 million in 2023, then grew by 6.38% to $16.1 million in 2024, then rose by 13.92% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Non-Current Deffered Revenue are $18.3 million (Q4 2025), $16.3 million (Q3 2025), and $16.6 million (Q2 2025).